Kedudukan dalam Saham
#40974
Verici Dx plc is an immuno-diagnostics company primarily focused on the kidney... Verici Dx plc is an immuno-diagnostics company primarily focused on the kidney transplantation sector. The firm specializes in creating both predictive and diagnostic assays for patients who have undergone kidney transplants. Its development pipeline features Clarava, a pre-transplant tool designed to forecast the likelihood of early acute rejection; Tuteva, a post-transplant assessment focusing on acute cellular rejection; and Protega, an innovative liquid biopsy aiming to predict the risk of fibrosis and eventual graft failure. Established in 2020, Verici Dx plc maintains its headquarters in Penarth, United Kingdom.
Perubahan (1 hari)
-0.48%
Perubahan (1 tahun)
-52.51%
Perdagangan Verici Dx plc (VRCI)
Harga VRCI dengan permodalan pasaran b
Modal pasaran bagi Verici Dx plc(VRCI)
Modal Pasaran: $56.59K
Sehingga August 2026, Verici Dx plc mempunyai modal pasaran sebanyak $56.59K. Ini menjadikan Verici Dx plc syarikat ke-40974th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Verici Dx plc dari 2020 hingga 2026
VRCI berbanding dengan 5 teratas yang paling popular stocks
| Harga VRCI |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.442T
|
+9,617,366,662.70%
|
|
|
|
|
$4.455T
|
+7,872,204,523.23%
|
|
|
|
|
$4.179T
|
+7,385,034,323.68%
|
|
|
|
|
$3.673T
|
+6,490,931,010.77%
|
|
|
|
|
$2.863T
|
+5,059,054,978.07%
|
